# EDGAR Filing Document

**Accession Number:** 0001766140
**File Stem:** 0001213900-26-065828
**Filing Date:** 2026-6
**Character Count:** 6224
**Document Hash:** 2e6773d55e034b2370f3b5d03579639c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-065828.hdr.sgml**: 20260605

**ACCESSION NUMBER**: 0001213900-26-065828

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 11

**CONFORMED PERIOD OF REPORT**: 20260605

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260605

**DATE AS OF CHANGE**: 20260605

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Unicycive Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001766140
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 813638692
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40582
- **FILM NUMBER:** 261069392

**BUSINESS ADDRESS:**
- **STREET 1:** 1975 W. EL CAMINO REAL, SUITE 204
- **CITY:** MOUNTAIN VIEW
- **STATE:** CA
- **ZIP:** 94040
- **BUSINESS PHONE:** 650-384-0642

**MAIL ADDRESS:**
- **STREET 1:** 1975 W. EL CAMINO REAL, SUITE 204
- **CITY:** MOUNTAIN VIEW
- **STATE:** CA
- **ZIP:** 94040

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**Current Report**

**Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 5, 2026**

**Unicycive Therapeutics, Inc.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-40582** | **81-3638692** |
| **(State or other jurisdiction<br> of incorporation)** | **(Commission File Number)** | **(IRS Employer <br> Identification No.)** |

---

**4300 El Camino Real, Suite 210**

**Los Alto, CA 94022**

(Address of principal executive offices)

Registrant's telephone number, including area code: **(650) 351-4495**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock | UNCY | Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 1.01. Entry into a Material Definitive Agreement.**

As previously reported, Unicycive Therapeutics, Inc. (the "Company") entered into a Sales Agreement, dated November 13, 2024, with Guggenheim Securities, LLC, as sales agent (the "Agent") as amended by Amendment No. 1 to Sales Agreement dated November 14, 2025, between the Company and the Agent (as amended, the "Sales Agreement"), to sell shares of its common stock, par value $0.001 per share (the "Common Stock"), having an aggregate offering price of up to $100,000,000 (the "Shares") from time to time, through an "at the market offering" (the "ATM Offering") as defined in Rule 415 under the Securities Act of 1933, as amended.

On June 5, 2026, the Company entered into Amendment No. 2 to the Sales Agreement with the Agent (the "Amendment") to increase the number of Shares that may be sold in the ATM Offering to $150,000,000. In connection with entering into the Amendment, the Company filed a Shelf Registration Statement on Form S-3, which includes a sales agreement prospectus (the "Registration Statement"), with the Securities and Exchange Commission on June 5, 2026, to sell shares of its Common Stock having an aggregate offering price of $50,000,000 in the ATM Offering.

The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of Amendment. A copy of the Amendment is filed as Exhibit 1.3 to the Registration Statement.

This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of any offer to buy the Shares or any securities, nor shall there be any offer, solicitation or sale of the Shares or any securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

---

| | |
|:---|:---|
| Exhibit No. | Description |
| 1.1 | [Amendment No. 2 to Sales Agreement, dated June 5, 2026, between Unicycive Therapeutics, Inc. and Guggenheim Securities, LLC (incorporated by reference to Exhibit 1.3 to the Shelf Registration Statement on Form S-3 filed with the Securities and Exchange Commission on June 5, 2026)](https://www.sec.gov/Archives/edgar/data/1766140/000121390026065819/ea029178901ex1-3.htm) |
| 104 | Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: June 5, 2026

---

| | |
|:---|:---|
| UNICYCIVE THERAPEUTICS, INC. | UNICYCIVE THERAPEUTICS, INC. |
| By: | */s/ Shalabh Gupta* |
| Name: | Shalabh Gupta |
| Title: | Chief Executive Officer |

---